Navigation Links
Omeros Corporation Reports Second Quarter 2012 Financial Results
Date:8/7/2012

SEATTLE, Aug. 7, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2012.

Financial ResultsTotal operating expenses for the quarter ended June 30, 2012 were $9.8 million compared to $6.1 million for the same period in 2011. The increase in operating expenses primarily relates to increased Phase 3 clinical trial expenses for OMS302 and OMS103HP and an increase in expenses in connection with preclinical work for Omeros' PDE10 and MASP-2 programs in preparation for their advancement into the clinic. For the quarter ended June 30, 2012, Omeros reported a net loss of $8.5 million, or $0.38 per share, compared to a net loss of $5.3 million, or $0.24 per share, for the same period in 2011.

At June 30, 2012, Omeros had cash, cash equivalents and short-term investments of $7.3 million. On July 2, 2012, Omeros completed a public offering pursuant to which it sold 3,365,854 shares of its common stock at a price of $10.25 per share for estimated net proceeds of $32.4 million. 

"Our two ongoing Phase 3 clinical trials continued to advance during the quarter – OMS302 for lens replacement procedures and OMS103HP for arthroscopic meniscectomy surgery – and we expect to report data for both in the second half of this year," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "We have also begun to prepare the NDA for OMS302 which, assuming positive data from the ongoing clinical trial, we expect to submit to the FDA during the first part of 2013.  Our other programs also progressed, and we plan to file an IND for our PDE10 inhibitor this quarter with an IND f
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces Discovery in MASP-2 Program
2. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
3. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
4. Omeros Prices $30 Million Public Offering of Common Stock
5. Omeros Announces Proposed Public Offering of Common Stock
6. Omeros to Present at Jefferies 2012 Global Healthcare Conference
7. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
8. Omeros to Present at Deutsche Bank Securities Health Care Conference
9. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
10. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
11. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2013)... , December 19, 2013 ... Technologies Corporation (NASDAQ: LIFE ), OncoMed Pharmaceuticals, ... (NASDAQ: HALO ), Infinity Pharmaceuticals, Inc. (NASDAQ: ... PTCT). Today,s readers may access these reports free of ... analyst ratings - via the links below. ...
(Date:12/19/2013)... Ill. , Dec. 19, 2013 PharMEDium, ... services, today announced an agreement under which a fund ... in the company. Oak Investment Partners and Baird Capital ... Management, an investment firm controlled by David N. ... retain an investment in the company. Terms of the ...
(Date:12/19/2013)... Dec. 19, 2013  E,Shee Clinical Esthetic ... cream product that is designed to target ... But, unlike other eye creams, this Alpha ... a scientifically-advanced blend of innovative ingredients.        ... restoration and care for the eyes and ...
Breaking Medicine Technology:Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics 2Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics 3Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics 4Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics 5Clayton, Dubilier & Rice to Invest in PharMEDium, Nation's Leading Provider of Sterile Compounding Services to Hospital Pharmacies 2Clayton, Dubilier & Rice to Invest in PharMEDium, Nation's Leading Provider of Sterile Compounding Services to Hospital Pharmacies 3Alpha and Omega Gene Therapy Eye Cream's Scientific Blend Removes Years of Damage 2
... , ... clinical stage company developing innovative treatments for depression and other ... today announced that data presented at a major medical meeting ... anxiolytic-like activity with no signs of the CNS-related side effects ...
... ... (Nasdaq: KERX ) announced today the initiation of a ... PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. ... Assess the Efficacy and Safety of Perifosine Added to the ...
Cached Medicine Technology:Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7
(Date:12/19/2013)... (PRWEB) December 19, 2013 Bariatric Eating, a ... announced today that beginning December, 2013, it will expand its ... Creme Brulee. Believe Vanilla Creme Brulee is a great tasting ... The Believe line of premium bottled drinks are now offered ... Latte , Italian Cappuccino , ...
(Date:12/19/2013)... VA (PRWEB) December 19, 2013 Implementing ... http://www.fdanews.com/RiskBased , Switching to risk-based verification and validation ... projects, plus reduce liability and recalls. , It’s a ... pushing companies to do it. , But like any ... all-new management report from FDAnews is just the ticket ...
(Date:12/19/2013)... MA (PRWEB) December 19, 2013 ... women experience heightened levels of stress during the ... some helpful suggestions in a recent Huffington ... Day Sacramento . Here are some ways busy ... 1.    Skip sending Christmas cards this year. Save time, ...
(Date:12/19/2013)... SuperSlow Zone® , a premier personal ... grand opening for their new location in Plum-Murrysville, Pennsylvania ... Dianne Lieb, are excited to be bringing this tried ... Pittsburgh area. , SuperSlow Zone® provides ... a Certified and Accredited SuperSlow Zone Instructor in a ...
(Date:12/18/2013)... Regenerative medicine may offer ways to banish baldness that ... Kobielak, MD, PhD has published a trio of papers ... Proceedings of the National Academy of Sciences ... when hair grows, when it stops growing and when ... Eve Kandyba, PhD, and their colleagues, the three publications ...
Breaking Medicine News(10 mins):Health News:Bariatric Protein Drink Released by Bariatric Eating 2Health News:FDAnews Management Report: Implementing Risk-Based Verification and Validation 2Health News:FDAnews Management Report: Implementing Risk-Based Verification and Validation 3Health News:Author Liz O’Donnell Helps Busy, Working Mothers Seek Sanity During the Holidays 2Health News:Author Liz O’Donnell Helps Busy, Working Mothers Seek Sanity During the Holidays 3Health News:Author Liz O’Donnell Helps Busy, Working Mothers Seek Sanity During the Holidays 4Health News:SuperSlow Zone Plum-Murrysville, is Proud to Announce Their Grand Opening 2Health News:SuperSlow Zone Plum-Murrysville, is Proud to Announce Their Grand Opening 3Health News:Stem cells offer clues to reversing receding hairlines 2
... cancers who receive radical chemoradiation have significantly better ... when compared with patients who have undergone a ... a study in the February 1 issue of ... journal of the American Society for Therapeutic Radiology ...
... The Obesity Action,Coalition (OAC) is calling on the ... 282 (HB 282) that discriminates,against those affected by obesity ... strongly feels that HB 282 is outright discrimination,against the ... attempts,proposed to address the obesity epidemic., Introduced in ...
... play in society, they remain among the most threatened ecosystems ... healthy wetlands for humans, the theme of this years World ... Wetlands, Healthy People. , According to the Ramsar Convention on ... more than 3 million people every year and brings suffering ...
... dance lessons, screenings offered to encourage healthy hearts, ... Month, and Baltimore Washington Medical Center has the key,to ... ), The medical center will host the fourth ... 2008 from 10 a.m. to 3 p.m. at the ...
... of the common Black Rat (Rattus rattus) has shed ... diseases around the globe. , Studying the mitochondrial DNA ... the world, an international team of scientists has identified ... each originating from a different part of Asia. , ...
... Dividend Provides An Annualized Yield Of 9.5%, LARGO, ... Board: UVICF) (TSX Venture Exchange: UVI) Board of Directors,today ... per common,share, payable February 28, 2008 to stockholders of ... "We are pleased to continue the quarterly dividend ...
Cached Medicine News:Health News:Larynx preservation preferred over total laryngectomy 2Health News:Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity 2Health News:Connection between health of wetlands and humans in focus 2Health News:Connection between health of wetlands and humans in focus 3Health News:Baltimore Washington Medical Center Hosts Day of Dance for Health 2Health News:Globetrotting black rat genes reveal spread of humans and diseases 2Health News:Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share 2
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
Straight, single action bone forceps to excise, trim and sculpt bone....
Palm Style Impactor Bone Awl with Ortho-Grip® silicone rubber handles and,stainless steel impactor caps....
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
Medicine Products: